This is notably evident in BRAF V600E mutations, where response to treatment varies by tumor type—requiring monotherapy in some cancers, a combination with MEK inhibitors in melanoma, and a combination with EGFR inhibitors in CRC to counteract feedback activation pathways and inherent resistance [133–136]. Here, MAP2K7 is linked to melanoma.